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ABSTRACT
Introduction Adherence monitoring to inhaled 
corticosteroids is an essential component of asthma 
management. Electronic monitoring devices (EMD) provide 
objective data on date, time and number of actuations. 
However, most give no information on inhalation. Novel 
EMD (NEMD) platforms have the potential to monitor both 
activation and inhalation.
Aim To assess the feasibility of NEMDs, in terms 
of usability, acceptability to patients and healthcare 
professionals and accuracy.
Methods This was an open- label, prospective, mixed- 
methods, pragmatic randomised study. Children with 
asthma attending specialist tertiary care were randomised 
to one of four NEMD: Remote Directly Observed Therapy 
(R- DOT), Hailie Smartinhaler, INhaler Compliance 
Assessment device (INCA) and the Rafi- tone App. Following 
monitoring, participants were invited to focus groups or 
one- to- one interviews. Usability and acceptability were 
evaluated using themes identified from the focus groups 
and interviews. Adherence accuracy was determined using 
adherence data from each NEMD.
Results Thirty- five children were recruited; 18 (51%), 
(11 males, median age 13.5 (7–16) years) completed 
monitoring, 14 (78%) provided feedback. Participants 
identified various features such as ease of use and 
minimal effort as desirable criteria for an NEMD. The Hailie 
and INCA fulfilled these criteria and were able to record 
both actuation and inhalation. Negative themes included a 
‘Big Brother’ effect and costs.
Conclusion There was no ‘one size fits all’, as participants 
identified advantages and disadvantages for each NEMD. 
Devices that can easily calculate adherence to activation 
and inhalation have the potential to have greatest utility in 
clinical practice. Each NEMD has different functionality and 
therefore choice of platform should be determined by the 
needs of the patient and healthcare professional.
INTRODUCTION
It is estimated that 5.4 million people in the 
UK are diagnosed with asthma, of which 
1.1 million are children.1 The UK has the 
highest rate of asthma deaths in Europe2 and 
young people in the UK are at higher risk of 
dying from asthma or having poorer quality 
of life than their counterparts in other high- 
income countries.3
Asthma accounts for a high economic 
burden with the National Health Service 
spending approximately £1 billion a year on 
asthma.3 The majority (90%) of these costs 
are attributed to asthma medications.4 Inap-
propriate use of medicines and suboptimal 
adherence results in higher healthcare costs 
and poorer health outcomes, including an 
increased risk of asthma attacks and hospital 
admissions.5
Key messages
What is the key question?
 ► Which novel electronic adherence monitoring devic-
es (NEMDs), that can measure both inhalation and 
activation is the most feasible to use as a tool for 
monitoring adherence in children aged 6-16 years 
with asthma in terms of accuracy, usability and 
acceptability?
What is the bottom line?
 ► NEMDs that have the ability to monitor actuation, 
inhalation and technique provide more accurate 
estimates of adherence to inhaled corticosteroids in 
children with asthma. Participants identified ease of 
use and lack of disruption to daily routine as desir-
able attributes of an NEMD.
Why read on?
 ► EMDs are increasingly used to measure adherence 
to asthma medications; however, there are limita-
tions. NEMDs address some of these limitations by 
assessing both inhalation and actuation. The parents 
and young people who participated in this study of-
fer unique insights into the utility of NEMDs in clin-
ical practice.
 ► The four NEMDs tested were found to have differ-
ent functionalities and therefore choice of platform 
should be determined by the needs of the patient 
and healthcare professional. The ability to monitor 
adherence remotely in real time is an added bonus 
in the current digital era. These devices could be uti-
lised in virtual clinics to monitor adherence remotely.
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A key aspect of improving adherence is being able to 
measure medication adherence accurately.3 4 6–9 However, 
this is challenging as clinicians’ ability to estimate adher-
ence is poor10 11 and parents and children often overes-
timate adherence in self- reports12 13 to please clinicians. 
Objective adherence measures such as dispensing data 
or electronic adherence monitoring using electronic 
monitoring devices (EMDs), are more accurate. EMDs 
attach onto inhalers and capture data on inhaler activa-
tion, timing of the activation and the number of doses 
activated. Several EMDs are available for asthma and are 
generally considered the ‘gold standard’ for adherence 
monitoring,8 9 14 15
EMDs have two key roles: (1) enabling healthcare 
professionals to interpret asthma control in the context 
of adherence and inform better decision making; and 
(2) as an intervention and tool for the patient to aid self- 
management and improve adherence. However, current 
EMDs only measure activation (eg, the depression of 
the inhaler canister) and provide no information on 
whether the inhaler was used correctly or if inhalation 
occurred.10 16 17
Several novel EMD (NEMD) platforms are currently 
in development which enable clinicians and patients to 
monitor both activation and inhalation, thus ensuring 
more accurate estimates of adherence and to better 
identify and address practical and perceptual barriers 
to adherence. However, to date only three studies on 
EMDs have assessed platforms which monitor activa-
tion and inhalation in asthma: two were on the inhaler 
compliance assessment device (INCA)18 19 studying accu-
racy, adherence rates and inhaler technique and one on 
mobile directly observed therapy (m- DOT),20 investi-
gating connectivity and usability as a primary outcome; 
only the latter study included children. The feasibility 
of these platforms in terms of usability, acceptability,21 
and accuracy of the EMDs to children, their families and 
healthcare professionals has not been explored. Under-
standing these three parameters, is key to ensure patient 
and healthcare professional engagement with these 
devices and ensure accurate decision making.
The aim of this study was to evaluate four NEMDs which 
have the potential to monitor both inhaler device actua-
tion and inhalation in terms of usability, acceptability and 
monitoring accuracy.
METHODS
This was a prospective, single- centre, open- label, prag-
matic randomised, mixed- methods study to explore the 
feasibility of using NEMDs in children with asthma at a 
specialist tertiary centre. Feasibility refers to the capa-
bility of the device to monitor adherence in clinical prac-
tice specifically investigating usability, acceptability and 
accuracy, using a qualitative and quantitative approach. 
Usability and acceptability of the NEMDs for patient and 
healthcare providers were assessed qualitatively using 
focus group discussions or one to one interview with 
children and their carers, and separately with paediatric 
respiratory Clinical Nurse Specialists (CNS). Device accu-
racy and impact on asthma outcomes were assessed by 
quantifying usable data from the devices and comparing 
adherence according to activation and correct inhalation 
and measuring asthma outcomes in the children. Ethical 
approval was obtained from the London Fulham Research 
committee and the Health Research Authority and the 
study was registered with  clinicaltrials. gov. General Data 
Protection Regulations were followed.
Study population
Children aged between 6 and 16 years with a diagnosis 
of asthma, prescribed inhaled corticosteroids (ICS) 
and attending the paediatric asthma clinic at the Royal 
Brompton Hospital (RBH), London, UK were recruited 
from October 2018 to May 2019.
Children’s CNS working with the asthma team at RBH 
were recruited for the CNS focus group.
Written, informed consent was obtained from the 
parent/carer, and CNS’, and consent or age appropriate 
assent from the child.
Figure 1 Novel Electronic Monitoring Devices used in the study
INCA, inhaler compliance assessment; R- DOT, remote directly observed therapy.
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Children were assigned to use one of the following four 
NEMDs for up to 12 weeks duration. All devices were CE 
marked and tested for safety (figure 1):
Hailie sensor (Adherium, New Zealand)
The Hailie is a battery powered electronic data logger 
which is suitable for attachment to a Turbohaler (eg, 
Symbicort). The sensor has an inbuilt electronic clock 
and calendar which logs the date and time of inhaler 
actuation. The device also contains a microphone that 
detects inhalation of the drug and a sensor for detecting 
the positioning of the Turbohaler.
Rafi-tone acoustic enabled smartphone APP (clin-e-cal, UK) 
with Flo-Tone (Clement Clarke, UK)
The Flo- Tone attaches to a metered- dose inhaler (MDI) 
and produces a sound when the inhaler is used correctly 
with a spacer. This sound activates a game which the child 
plays as they are inhaling the dose. The game only func-
tioned when the correct flow was generated through the 
spacer for the Flo- tone to make a noise, which is detected 
by the App and drives the game. A record of the date 
and time the game was played is logged on a tracker. The 
game is aimed at younger children (6–11 years). It was 
designed as an incentive tool to improve inhaler tech-
nique for younger children and adapted for this study to 
record inhaler use.
INhaler Compliance Assessment (INCA_device (INCA, Ireland)
The INCA is an electronic data logger that attaches to a 
Diskus/Diskhaler dry powder inhaler (eg, Seretide Accu-
haler). This device measures adherence using an audio 
recording. An inbuilt analysis of the digital audio record-
ings enables objective assessment of inhaler use and tech-
nique.
Remote Directly Observed Therapy (R-DOT)
The R- DOT platform monitors adherence by filming 
inhaler use, using a Smartphone. The clip is then 
uploaded via a secure website (Continga, UK). The 
clips were reviewed by a Paediatric asthma CNS to assess 
inhaler technique using the seven step inhaler checklist 
from the UK inhaler group.22 These were classified into 
effective if all seven steps were followed correctly, poor if 
none were followed and partially effective if at least one 
to six steps were followed correctly.
A pragmatic approach was used for recruitment, based 
on the child’s age and inhaler type as each device fitted 
different inhaler types. Blinding was not possible as the 
devices were easily identifiable. A sample size of 30 was 
initially selected, 10 in each arm (Hailie and R- DOT) and 
5 each in Rafi- tone and INCA, as the Rafi- tone is aimed 
at younger children (6–12 years)and older children were 
recruited for the INCA arm as good inspiratory flow is 
needed for the Accuhaler.
Patient and public involvement
The lay summary was formally reviewed externally by 
young people with asthma and their parents. Their 
insightful and useful suggestions were incorporated into 
the study design and design of information sheets and 
the proposed study improved as a result.
Additionally, this is largely a qualitative study and there-
fore the views of children and their parents/carers has 
been the focus of this study. The results of the study were 
discussed in the focus groups/interviews conducted.
Usability and acceptability: a qualitative study
Separate topic guides were used to obtain qualitative 
feedback on the acceptability and usability of the devices 
for children/parents and CNS’. A second researcher 
(CP) provided support in both focus group discussions 
to minimise bias. All discussions were audio recorded 
and transcribed as ‘intelligent verbatim’. The qualita-
tive data were analysed using Braun and Clarke’s six step 
process for conducting thematic analysis consisting of 
an initial familiarisation step of reading transcripts while 
listening to audio recordings.23 An inductive approach 
was then used to code the data. Initially complete coding 
was conducted using participant transcripts, followed by 
second and third coding. Themes and sub themes were 
identified until thematic saturation was reached, then 
categorised and reviewed before writing up. Twenty five 
percent of the transcripts were randomly chosen and 
double- coded by an independent researcher (AC) expe-
rienced in qualitative research in line with other qualita-
tive studies which recommend ~ 20%24 25 as a method of 
analyst triangulation.
Accuracy of NEMDs : a quantitative study
Accuracy of the NEMD was determined by the adherence 
data collected from the devices as percentage of doses 
activated, inhaled and where appropriate correct tech-
nique. Asthma control was measured by using the asthma 
control test (ACT)26 for children ≥12 years or childhood 
ACT (cACT)27 for children <12 years; quality of life was 
assessed using the mini Paediatric Asthma Quality of Life 
questionnaire (mini PAQLQ)28 29; fractional exhaled 
nitric oxide (FENO)30 was measured using a NIOX 
VERO: Aerocrine, Stockholm, Sweden; spirometry for 
forced expiratory volume in 1 second (FEV1), forced 
vital capacity (FVC)30 31; and bronchodilator reversibility 
(BDR)32 33 were measured using a Vitalograph, Buck-
ingham UK spirometer. These were conducted as part 
of routine clinical care assessments at the beginning and 
end of the monitoring period.
RESULTS AND ANALYSIS
A total of 52 patients were identified as eligible for inclu-
sion, of whom, 35 (66% male, median age 12 years) 
consented to participate, and were randomised. Of these, 
18 (51%) completed monitoring, 14 (78%) provided 
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feedback, 7 (20%) were lost to follow- up, 4 (11%) expe-
rienced device failure, 4 (11%) lost their device or it 
was thrown away and 2 (7%) withdrew. The Consoli-
dated Standards of Reporting Trials diagram is shown in 
figure 2.
The duration of monitoring for each device varied: the 
median number of days of Hailie monitoring was 88.5 
days (range 6–120), Rafi- tone 25.5 days (range 25–26) 
and R- DOT 54 days (range of 8–145). The length of 
monitoring was longer in the R- DOT and Hailie arm as 
recruitment occurred earlier in the study.
Usability and acceptability: qualitative data results
Of the participants completing monitoring, 14/18 (78%) 
participated in the focus groups or individual interviews. 
Of these, four participants and their parents attended 
the focus group meeting, eight participants were inter-
viewed individually face to face and two participant were 
interviewed over the telephone.
The duration of the patient focus group was 63 min; 
individual interviews were a mean 15.3 (SD ±8) min.
For the healthcare professional focus group, all of the 
three invited CNS attended the focus group meeting. 
The focus group lasted 56 min.
Four key themes influencing patient and healthcare 
professional engagement were identified from these 
focus groups and interviews:
 ► Functionality of the device.
 ► Usability of the device.
 ► Perceptions and emotions.
 ► Enhancements, improvements and preferences.
These are described below—full tables of quotes have 
been included in the online supplemental 1.
Figure 2 CONSORT flow diagram for NEMD study. ADHD, attention- deficit hyperactivity disorder; ASD, autistic spectrum 
disorder; Safeguarding concern: child in need plans were in place or about to be placed. CONSORT, Consolidated Standards 
of Reporting Trials; DOT, directly observed therapy; INCA, inhaler compliance assessment; NEMD, novel electronic monitoring 
device; R- DOT, remote DOT.
copyright.
 on A











es: first published as 10.1136/bm










The INCA and Hailie were considered by both patients 
and CNS, the most accurate and reliable followed by 
R- DOT as it only records adherence to video uploads.
An adolescent commented ‘I think with the Hailie, it’s 
quite black and white. You've either done it properly or you 
haven't’ (NEMD1).
Another adolescent using R- DOT stated: ‘I took the 
inhaler just not the video’(NEMD31).
Rafi- tone was considered to be less accurate, as 
observed by the CNS’ as the App records the sound 
of the Flo- tone and did not differentiate the inhaler 
type, ‘with the Rafi tone it’s just attached to the spacer, the 
inhaler that they’re using could be their preventer or it could 
be their reliever’ (CNS1).
Assessment of inhaler technique
Both R- DOT and Rafi- tone were perceived to help with 
improving technique. Although Hailie and INCA assessed 
technique, interventions could not be implemented until 
the patient returned to clinic and the data downloaded.
An adolescent reflected: ‘one good thing about the 
R- DOT was the technique thing, which for me was 
important’(NEMD1).
A child described how the Rafi- tone ‘makes me feel 
like I know how to do my pump more, and I can actually 
use it to help me out with my breathing’ (NEMD 34). 
A CNS commented that the Rafi- tone is ‘Good if 
we’ve got concerns about someone that has dysfunctional 
breathing’(CNS 1).
Notifications, reminder and display functions
Notifications, reminders and visual data display were 
reported as positive attributes of the Hailie.
An adolescent commented: ‘So, when I was using the 
Hailie I thought it was pretty good because when…on my 
phone there would pop up a notification. And then I'd take 
it’ (NEMD 18).
Data access and analysis
An adolescent felt that with the Hailie: ‘I just think it’s 
having my data there, would just help me to remember to 
take it more’ (NEMD 4).
Usability of device
Ease of use
Children, parents/carers and CNS’ considered the 
Hailie and INCA easier to use as they attached directly to 
the inhaler, did not affect routine and required minimal 
effort.21
With the Hailie an adolescent felt that ‘it’s just the easiest 
thing, as I said, fast mornings, just take it normally. So, yes, if 
you want to do the bare minimum, the Smartinhaler/Hailie is 
good for that’(NEMD 4).
The R- DOT often needed two people and was considered 
to require effort, affected routine and some adolescents felt 
it diminished independence and autonomy.
An adolescent commented on R- DOT ‘you can't film 
yourself, that’s the issue. So, mum had to film me’(NEMD1). 
The participant’s mum commented ‘It wasn't the fact 
that it took time, it was the fact that we had to coordinate’. The 
same adolescent commented: ’for me, when I have a set 
routine that I get up and straight away I have my inhaler, it 
doesn't work as well because then you've got to sort out a time 
that works for everyone’ (NEMD 1).
However, R- DOT provided physical evidence to parents/
carers/healthcare providers that the medication was 
actually taken correctly as commented by one of the 
participant’s parent: ‘For me, recording, it’s better because I 
can see how [the participant’] doing. Sometimes [the participant] 
doesn't do it properly when [the participant] doesn't have time. 
But if I record [the participant] I can see how [the participant’s] 
doing it properly’ (Parent of NEMD2).
Cost-effectiveness
The cost of the device and reusability was considered 
by participants to be important. One CNS commented 
‘The problem is that if you have a very expensive device in a 
disposable form, [i.e. INCA] you throw away the inhaler 
afterwards. You've got to be able to take it off and attach it to 
your next one’ (CNS1).
Independence
Independence and autonomy were considered by 
children to be valuable with one adolescent in the INCA 
arm stating: ‘my mum and dad can be there to say to take it 
but at the end of the day they can't force me to take it. I have to 
take that step. So, I think by getting rid of them telling me to take 
it and me just remembering myself or be reminded would really 
help me to take the step forward and actually benefitting from the 
medicine’ (NEMD5).
This was reflected also in the CNS’ perspectives: ‘obviously 
if you’re like 14, 15, 16 years they don’t want their mum or 




One parent in R- DOT arm felt that monitoring was to 
keep an eye on them ‘To fault parents to see if they are doing 
it wrong because I personally think that’s what it is, to say, yeah, 
you are not doing this right’ (parent of NEMD 32).
Emotions
Emotions such as embarrassment due to personal 
or domestic appearance were expressed by some 
participants using R- DOT. A child said ‘I don’t feel I look 
nice, and I don’t want to be videoed. Sometimes, oh my hair is 
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not right. And then I think in my head, oh, it doesn’t matter 
they know that sometimes in the morning having like crazy hair’ 
(NEMD 32).
A parent using R- DOT felt ‘so you're sitting there thinking 
I've got to get a headshot because [the participant’s] not dressed. 
It’s things like that. And [the participant’s] room’s a tip and 
you're thinking oh crikey’ (NEMD 1).
Changes in behaviours
Some participants reported that monitoring per se led 
to behaviour change as described by this adolescent 
using Hailie: ’When I'm taking my inhaler sometimes, I realize 
that I’m being monitored. So that gives me a little boost and just 
try and do it properly. Because I remember oh, they're monitoring 
me, so I want to get good results. I think that’s why I do it’ 
(NEMD 10).
Improvement and personal preferences
Expression of personal preferences
In the focus group, most had previously been monitored 
using an EMD (Smartinhaler). The Hailie was felt to have 
many positive attributes as it had the ability to show adher-
ence data in visual format such as bar charts, required little 
additional effort and time, provided instant feedback on 
percentage adherence in clinic and was able to monitor acti-
vation, inhalation and correct orientation of the device.
‘I think the Halie is a better choice because if it’s programmed and 
you know you’ve got to take it, and if you’ve forgotten it, it will remind 
you’ (NEMD 18).
‘You can get a lot of data from a single device, you can see kind of 
patterns of when they’ve done it with the Hailie’(CNS1).
Recommendations on improvements
In terms of suggestions for improvements, participants 
wanted to see their own adherence data on their phone to 
act as a reminder. Others wanted instant feedback on their 
technique especially when they are unwell.
‘Like seeing what I’ve visually taken, would just help me to 
remember to take more, because then when you’re feeling bad at 
the end of the week you look back and you think actually, I forgot’ 
(NEMD18).
One adolescent compared the Hailie with a previous 
EMD ‘So that’s very useful. Because previously with a 
Smartinhaler we had no idea what the data was you were getting, 
or this data and we didn't know what was happening day- to- 
day. So, to get that feedback instantly… is useful’(NEMD1).
Concept of personalised adherence monitoring
Being able to personalise the NEMD according to the needs 
of the patient was discussed as important, as reflected in the 
quote from one of the CNS:
‘I think probably depending on the patient…for parents who 
kind of want to distract them into taking their inhaler they would 
probably like the Rafi- tone, then for those who are independent, 
are getting a bit older, the Hailie is the way forward depending 
on age, then those with inhaler technique issues R- DOT, biggest 
thing is what would work’ (CNS1).
Accuracy and impact on asthma outcomes: quantitative data 
results
The median (range) adherence for R- DOT was 72% (51%–
94%) for Hailie 65% (50%–100%) and for Rafi- tone 87% 
(82%–92%) Insufficient INCA devices were returned to 
calculate adherence.
Comparison of type of adherence data collected from the 
Hailie can be seen below (table 1).
The median (range) adherence to video uploads with the 
R- DOT was 73% (64%–94%) based on duration of R- DOT 
usage (table 2). There was no intervention during the moni-
toring period.
Inhaler technique was assessed to be effective (>80%) 
in 3/8 children and partially effective in 5/8 with only one 
occurrence of poor technique (table 3).
Impact on asthma control
Baseline and follow- up scores for ACT/cACT, m- PAQLQ, 
FENO, spirometry and BDR for the different groups are 
reported in supplementary material (online supplemental 2 
and 3).
Acceptability criteria
The characteristics of each of the NEMD in terms of usability, 
acceptability and accuracy were amalgamated and used to 
devise a list of acceptability criteria by the research team and 
an expert panel (consisting of paediatric respiratory consult-
ants, CNS and pharmacist) who reviewed the study results 
box 1.
DISCUSSION
This is the first study to explore the feasibility of four NEMDs 
for use in children with asthma using both qualitative and 
quantitative methods.













NEMD4 63 58 24
NEMD8 73 52 5
NEMD18 50 50 25
NEMD11 52 50 22
NEMD12 100 72 25
NEMD10 53 30 28
Mean (SD) 65 (19) 52 (13) 22 (8)
NEMD, novel electronic monitoring device.
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The key finding was that devices that use objective 
measures of activation, inhalation and technique which 
are accurate, require least effort, are easy to use and fit into 
existing routines of children and carers were preferred by 
children, their carers and healthcare professionals. Other 
ideal characteristics include cost- effectiveness as expressed 
by CNS, flexibility to set up reminders with notifications as 
suggested by children, and ability to provide visual display of 
adherence data in real time which was desired by both chil-
dren and healthcare professionals.
The four platforms were chosen for this study as they use 
different methodologies to assess inhaler technique. Advan-
tages and disadvantages were identified by participants for 
each. The Hailie and the INCA were popular with both chil-
dren and CNS’ due to their ease of use and minimal addi-
tional effort required on the part of the child. The Hailie 
has the ability to detect adherence in real time calculating 
percentage adherence easily, though this function was not 
enabled in our study. Furthermore, it provided useful data 
for healthcare professionals on individual components of 
inhaler technique. However, both the Hailie and the INCA 
devices are specific to a single type of inhaler device: the 
Turbohaler and Accuhaler, respectively. These are both 
breath- actuated inhalers and require adequate inspiratory 
flow to use, which younger children may find difficult to 
generate. Of note, recruitment in the block for the INCA 
device was low as most children who are prescribed Seretide 
in our clinic use the MDI version not the Accuhaler. Unfor-
tunately for the INCA block, no usable adherence data 
were obtained as the devices were thrown away or not fitted 
correctly. This is in contrast to the study by Sulaiman et al in 
adults which demonstrated the utility of the device for moni-
toring inhaler use and technique.19 Many of the advantages 
identified with the Hailie, such as ease of use, requiring no 
extra steps are also relevant to the INCA. At the study site, 
an MDI with a spacer was the most frequently used inhaler 
type. Unfortunately, there were no devices available at the 
time of the study which had the usability and functionality 
of the Haile and INCA, and could also be used with an MDI 
and spacer.
The Rafi- tone App was designed to help young children 
improve inhaler technique and to incentivise inhaler use via 
a game. This was adapted by the developer of the Clin- e- cal 
App for this study to record adherence. The App is aimed at 
younger children and therefore we limited recruitment to 
this block to children aged 6–11 years. Feedback from parents 
was positive in terms of the impact on technique. However, 
the current functionality of the App is limited to collecting 
data when the correct pitch is heard from the Flo- tone. It is 
not possible to know which inhaler was used, the number of 




No of days R- 
DOT usage
No of videos 
uploaded
No of days missed at 
least one video upload
% adherence to video uploads 
based on duration of usage
NEMD1 11 weeks 76 106 40 70
NEMD2 10 weeks 70 105 32 75
NEMD11 36 weeks 84 158 10 94
NEMD14 21 weeks 84 70 16 83
NEMD15 1 weeks 8 6 2 75
NEMD16 2 weeks 13 18 7 64
NEMD31 33 weeks 84 55 46 66
NEMD32 5 weeks 35 46 19 66
NEMD, novel electronic monitoring device; R- DOT, remote directly observed therapy.


























NEMD1 E E E PaE E PaE E E E PaE PaE PaE
NEMD2 PaE PaE PaE PaE PaE PaE PaE PaE PaE PaE NR NR
NEMD11 E PaE E PaE E E E E E E E E
NEMD14 PaE PaE P PaE PaE PaE PaE PaE PaE PaE PaE PaE
NEMD15 E E NR NR NR NR NR NR NR NR NR NR
NEMD16 E E NR NR NR NR NR NR NR NR NR NR
NEMD31 PaE PaE PaE PaE PaE PaE PaE PaE PaE PaE PaE PaE
NEMD32 PaE PaE PaE PaE PaE NR NR NR NR NR NR NR
CNS, clinical nurse specialist; E, effective; NEMD, novel electronic monitoring device; NR, no recording; P, poor; PaE, partially effective; 
UKIG, UK Inhaler Group.
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puffs used or if the Flo- tone was even attached to an inhaler. 
This limits the utility of this platform for monitoring ICS 
adherence (for which it was not originally designed). Addi-
tional effort was required on the part of the parent/caregiver 
to ensure that the App was open at the time the inhaler was 
given. Nonetheless based on our study findings, an App for 
children which incentivises inhaler use, particularly one that 
rewards good technique, has the potential to be an effective 
intervention that merits further study and consideration.
The R- DOT platform was the only platform capable 
of monitoring use for all types of inhaler devices, which is 
particularly advantageous given the number of different 
inhaler types now available. It also enables technique to be 
assessed by a trained professional and ensures that all aspects 
of inhaler technique are checked. Furthermore, feedback 
can be given rapidly to correct technique. In our study, it was 
not possible to review inhaler technique in real time, due to 
logistical constraints and there was no intervention during 
the monitoring period. In a pilot study of this device, positive 
user feedback was reported with improvement in technique 
over successive weeks of monitoring and intervention.20 In 
contrast, some of the comments in our study from children 
reflected concerns about filming themselves. This was partic-
ularly the case among adolescents who were concerned 
about their appearance. Although this platform is excellent 
for information on technique it provides little definitive 
information on adherence. Failure to record a video does 
not necessarily mean that the inhaler has not been used. 
Parents highlighted the difficulties of fitting this in to a busy 
routine. It is possible that if this change in routine could 
be achieved in the short term, it might lead to longer- term 
behavioural change where correct inhaler use is embedded 
in the daily routine.2 CNS' felt that this was a good way to 
assess technique; however, reviewing the videos took time 
and they do not currently have the capacity to do this outside 
of a clinical study. Advantages with the R- DOT included the 
physical evidence that the dose was taken correctly enabling 
remote offsite monitoring of children with provision of 
instant feedback.
The main strength of this study is that it is the first time 
that the INCA, Rafi- tone and Hailie have been used as adher-
ence monitoring tools in a real- world setting in children, and 
compared using both quantitative and qualitative methods.
The main limitation of this study is the small sample size 
which did not enable robust quantitative statistical analysis 
of the data. This study took place within a specialist tertiary 
asthma clinic and the findings may not be generalisable to 
the general population of children with asthma, particu-
larly in primary care. Further evaluation of these NEMDs 
in a wider population is warranted. However, many of the 
findings are pertinent across care settings, particularly those 
relating to cost and impact on the workload of healthcare 
professionals. The acceptability criteria developed from our 
findings could potentially be used for testing future NEMDs.
CONCLUSION
There is no ‘one size fits all’ NEMD and there were advan-
tages and disadvantages identified for all the devices tested. 
The choice of device needs to be tailored to the needs and 
preferences of the patient based on improving technique or 
monitoring adherence, and there is a place for personalised 
adherence monitoring. The data from this study can inform 
the development of an ideal device which combines the key 
functionalities of each of the platforms. Device selection 
needs to be versatile and compatible with all inhaler types, 
provide accurate adherence monitoring, require minimum 
additional effort on the part of the child and their carer, 
and be able to provide real- time visual adherence data to 
patients and healthcare professional, including accuracy and 
Box 1 Acceptability criteria to assess device characteristics
Characteristics
 ► Accuracy
Activation of dose recorded.
Inhalation of dose recorded.
Technique assessed.
 ► Minimal effort
 ► Minimum amount of time.
 ► Fits in with daily routine.
 ► Ability to set notifications and reminders.
 ► Allows independent monitoring.
 ► Ability to display visual data to children/carers.
 ► Ability to display data to healthcare professionals.
 ► Easy data analysis.
 ► Ability to easily upload data in clinic.
 ► Ability to correct technique.
 ► Reliable adherence monitoring.
 ► Cannot be thrown away/lost.
 ► Minimal cost of device.
 ► Flexibility to fit all inhaler types.
 ► Technology issues.
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feedback on technique. Our study identified the factors that 
influence device usability and acceptability and provided 
early data on the accuracy of these devices. Further studies 
are now warranted to evaluate how these findings can be 
applied to interventions to improve adherence, use in virtual 
clinics and how using these devices influence adherence and 
asthma outcomes
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Supplementary Table 1: 
Quotes from Participants grouped into main and subthemes. 
Main Theme: Functionality of device 
Sub theme Quotes 
Accuracy   R-DOT: ‘If I'm leaving early in the morning then he's got no way of videoing. So, I 
was constantly texting you saying I'm working early this week, not going to be able 
to video. And I know he was taking it, but you had no data’.(NEMD1) 
‘For me, recording, it's better because I can see how he's doing. Sometimes he 
doesn't do it properly when he doesn't have time. But if I record him I can see how 
he's doing it properly’.(NEMD2) 
Hailie: ‘I think with the Hailie, it's quite black and white. You've either done it 
properly or you haven't. (NEMD1) 
‘And I just feel like, there’s less room for manual error’. (NEMD 4) 
Rafi-tone: with the Rafi tone, obviously if it’s just attached to the spacer, the inhaler 
that they’re using, it could be their preventer, it could be their reliever(CNS1) 
Reliability R-DOT: ‘I took the inhaler just not the video’.(NEMD31) 
’And I think something that actually records when you've taken it, not when you've 
forgotten to film or something. with this you could still take the Seretide and it might 
not show up because you've forgotten to film it or something’(NEMD1) 
’Something happened with the Wi-Fi,(NEMD 31) 
So there is occasions where battery has died and you wake up and it's not coming 
on’(NEMD 32) 
Hailie: ‘Because with the Halie it works if you take it, and if you don't take it, it 
doesn't work’ 
Rafi-tone: ‘if I’m away at the weekend my son doesn’t come with me.  So, because 
it’s on my phone then he still uses the inhaler, but obviously, it doesn’t record it 
because I’m away (NEMD 34) 
INCA: The problem is that you then have a very expensive device in a disposable 
form, yes? You throw away the inhaler afterwards. You've got to be able to take it 




R-DOT: one good thing about the R-DOT was the technique thing, which for me I 
felt was more important. 
Because when you're taking an inhaler sometimes, especially if you're not well your 
technique can be a bit iffy. Sometimes you can be hunched over or not take enough 
breaths or something like that. So that's quite useful’. (NEMD1) 
Rafi-Tone: ‘It just makes me feel like I know how to do my pump more, and I can 
actually use it to help me out with my breathing’. (NEMD 34) 
I think maybe the Rafi tone would be good if we’ve got concerns about someone 
that’s maybe a bit dysfunctional or has got issues with inhaler technique, I think that 





Hailie: ‘So, when I was using the Halie I thought it was pretty good because 
when…on my phone there would pop up a notification saying I needed to take it. 
And then I'd take it because obviously I got reminded’.(NEMD 18) 
Technical 
issue 
Hailie: Yeah, like it was showing that he took three in the morning and none of a 
night, when he'd have two in the morning and two of a night (NEMD 18) 
R-DOT: It came up black and then it wouldn’t use it, so when we pressed 





Hailie: ‘I just think it’s having it there and having my data there, would just help me 
remember to take it more.   Like seeing what I’ve visually taken, would just help me 
to remember to take more...make me just, you know, remember to take it.’ (NEMD 
4) 
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R-DOT ‘We couldn't view anything. This is what I'm saying, we couldn't see 
anything. All we got is that the video had been sent successfully. That was it. So, I 
had no idea. Well, I knew because I was filming him each time. But in terms of how 
many times I'd videoed him, how many times I'd missed, I had no idea’.(NEMD 1) 
Aesthetics INCA: ’Just because if you want to try and get it in a bag, then it was poking out, so 
it's not exactly ideal to have it poking out and then you try and sit on where it's 
poking 
A bit big to fit in my pocket, so I’d have to bring my school bag with me if I was to 
take it out with me, like at a sleep over, for example’.  (NEMD 5) 
 
 
Main Theme: Usability of device 
Sub theme Quotes 
Ease of use R-DOT: ‘But you can't film yourself, that's the issue. Because you're 
taking…you've got the inhaler in one hand, you can't then have the phone in the 
other hand or something. But I think it's quite tricky. So, mum had to film me 
every day, which meant it had to be a time that worked for both of us’. (NEMD1) 
Hailie: ’Personally, for me, it’s just the easiest thing, as I said, fast mornings, I just 
take it normally and it’s recorded (NEMD4) 
Rafi-tone: ‘Yes, very easy.  And even easy to send it over by email’ (NEMD 34) 
INCA: ‘We probably don’t have enough kids on accuhalers to actually really justify 
INCA’ (CNS2) 
Effort R-DOT: ‘It wasn't the fact that it took time, it was the fact that we had to 
coordinate. So, I often leave for work just as he's waking up. And then if I go 
upstairs, I'm ready to leave, I'm sitting there screaming saying get out of the 
bathroom. Or get out of bed so that I can video you. Oh my god’(NEMD 1). 
‘I personally think we put a lot of effort in’. You can't do it on your own.  We 
always have to do it together don’t we.  She holds the phone and I do it.  You 
need two people’ (parent of NEMD32) 
I think it’s just another thing to remember.  It’s also really awkward not like, having 
to find the website and stuff (NEMD 15) 
Hailie: So, yes, if you want to do the bare minimum, the Smartinhaler/Hailie is 
good for that,(NEMD 4) 
‘I think the Hailie was more easy, you can carry it around. You don't need a 
phone to do it. And you could do it anywhere. I think it was quite better, more 
suitable’(NEMD 4) 
Rafi-Tone: ‘‘Yes, very easy.  And even easy to send it over by email’ (parent of 
NEMD 34) 
Time R-DOT: ‘it's a huge amount of time, because it's a minute a day per person 
roughly, and then the time it takes you to analyse. 
So, if you have so many people doing that one, and having to watch all those 
videos’ (NEMD 1) 
‘It’s going to be a big time constraint, especially if you want to…if for instance, for 
example, you want to be able to show them, aside from the video, but like 
objective, like make a graph or something, you’re really going to have to be 
methodical in what you do and it’s going to take a lot of time to be able to make 
that graph up, which is a shame. They could tweak that on the platform, I think 
that would be good (CNS 1) 
Rafi-tone: ‘Not long really, and now he’s quite clued up he knows how to load it 
up on my phone as well, he quite often just does it himself’ (NEMD 34). 
 
Routine R-DOT: ‘So, mum had to film me every day, which meant it had to be a time that 
worked for both of us. Which meant that for me, when I have a set routine that I 
get up and straight away I have my inhaler, it doesn't work as well because then 
you've got to sort out a time that works for everyone’ (NEMD 1). 
‘Especially in the mornings because you are trying to get ready for school as well, 
and it's downloading or something.  We did have that issue, where I have just 
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done it and left it and thought, I can't do it now I haven’t got time’ (Parent of 
NEMD32). 
Hailie: ’Nothing changed for us. No routine changed, did it? Nothing changed. 
You just done it as normal’ (NEMD 18). 
Rafi tone: ‘It’s okay, it just annoys me how I have to get up earlier than I do. 
Because when I take it, I have to do it when my Mum’s in’ (NEMD 34). 
 
Cost effective INCA:‘The problem is that you then have a very expensive device in a disposable 
form, yes? You throw away the inhaler afterwards. You've got to be able to take it 
off and attach it to your next one’ (CNS 1) 
 
Independence R-DOT.‘That’s like what I was saying about showing my mum how I do it.  I think 
if you are videoing yourself taking it, it's kind of like them needing to see you 
taking it, where I feel if it was to just record you as taking it, that’s more like the 
trust and independence of them, saying yes he is taking it and we can trust him to 
do it’ (NEMD 5). 
Hallie: I feel like it's better because at least I know I've taken it and I don't need…I 
don't need someone to keep reminding me, if that makes sense’(NEMD18). 
‘And you can't remind a teenage’ (Parent of NEMD18). 
INCA: I like the independence actor because the doctors and the nurses at the 
hospital is always telling me how, like, my mum and dad can be there to say to 
take it but at the end of the day they can't force me to take it.  Like, I have to take 
that step.  So, I think by getting rid of them telling me to take it and me just 
remembering myself or be reminded myself standing up for myself would really 






Main Theme: Perceptions and emotions 
Sub themes Quotes 
Big brother R-DOT: To fault parents to see if they are doing it wrong because I personally 
think that’s what it is, to say, yeah, you are not doing this right.  Because even 
with the Smartinhaler, that was there for a purpose and it was like, you are not 
doing this right and this one is more like personal, because that one they can't film 
you but this one you can and you are seeing it and it's to say, actually it's not us 
it's you’ (Parent of NEMD 32). 
INCA: I felt like when you have a monitor you could be really good taking your 
inhaler but then as soon as you know someone is checking how you take it you 
start to panic and then when you are panicking about it you forget more, I think.  
Because you are wondering, have I taken it, then in your head, you are thinking, 
of course, I’ve taken it because they are going to check it but then you haven’t 
actually taken it’ (NEMD 5). 
 
Emotions R-DOT: And it's all that thing that I'm getting ready to leave for work and he's not 
quite dressed yet, so you're sitting there thinking I've got to get a headshot 
because he's not dressed. It's things like that. And his room's a tip and you're 
thinking oh crikey’ (NEMD 1). 
‘I don’t feel I look nice, and I don’t want to be videoed. sometimes, oh my hair is 
not right. And then I think to my head, oh, it doesn’t matter they know that 
sometimes in the morning having like crazy hair’ (NEMD 32). 
‘I don’t know, I just find it a bit weird. I think the video.  I just found it a bit weird’ 
(NEMD 15). 
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Behaviours Hailie: ’When I'm taking my inhaler sometimes, I realise that I'm being monitored. 
So that gives me a little boost and just try and do it properly. Because I remember 
oh, they're monitoring me, so I want to get good results. I think that's why I do it.’ 
(NEMD 10) 
‘I don’t remember forgetting it, but I mean, I’m sure I do.  I mean, yes, but if I’m 
waking up, if I wake up late and I’m late for school or something.  But yes, I’m 
sure there will have been times when I have forgotten it’ (NEMD 4). 
‘He's saying he doesn't change, but I think he changes when I'm monitoring him’ 
(Parent of NEMD  10). 
‘I could say to him though before don't forget, and you'd forget, wouldn't you? 
Within a minute he's forgotten. 




Main theme: Enhancement, improvements and preferences 




Hailie: ‘notification that he took it well or didn't take it well’ (NEMD 18). 
Yeah, the technique one, definitely, because then you know if you haven't… 
You might be taking it for several days with the technique not being great, it's 
not really being that useful, is it, to him then. So yes, so the technique thing, if it 
flashed to say yes, tick, that he's taken it properly, correctly, he's got the correct 
dose. That would be brilliant actually’ (Parent of NEMD 10). 
R-DOT: ‘Maybe put in an app, so all you have to do is click on the app and then 
you’ve got everything there, and you kind of video it or just say that you’ve done 
it.  So, they can see when you’ve done it, and if you’ve done it 
Yeah.  I think it would be quite useful to see how often you do it.  So, it gives 
you a percentage of how often you do it’ (NEMD 15). 
’Maybe it could give a message on the phone saying you have taken this’ (nemd 
31) 
INCA: ‘But I guess, something that you can either connect to your phone or tell 
you itself, like on a reader saying, for example, taken one out of two, so I know I 
have taken it in the morning or I haven’t taken a second puff today, or just 
something that you can connect it to…I know you guys can connect it to your 
computers here.  Maybe if we could use a general charger we could connect it 
to our laptops, for example, and then open up a programme that we download 
and it shows the graph on how long we have been going’ (NEMD 5). 
 
Preferences Hailie: ‘Yeah.  I think the Halie is a better choice because if it’s programmed and 
you know you’ve got to take it, and if you’ve forgotten it, it will remind you, you 
know you’ve got to take it, and you…because you’ve had a condition so you 
can’t not forget to take it.  And I think this is a better one’ (NEMD 18). 
‘Really good, I like them. You can get a lot of data from a single device, not just, 
have you used it, yes or no, not a total…you can see kind of patterns of when 
they’ve done it, have they done…is it a morning person, is it an afternoon 
person, whether they’ve dose dumped, you can get just the biggest scope of 
information. However, the ones that we’ve got at the moment can see the 
biggest disadvantage, you can’t see flow, it is re-actuation, so if you’ve got 
someone that’s clever then they could just conveniently just do a twist and not 
do it, I don’t know’ (CNS1). 
‘personally, I would say the Smartinhaler is already a pretty good system.  And 
there obviously could be some tweaks made to that, I can’t say completely what 
they should be, but I think it’s so far, pretty good (NEMD 4) 
‘So, I preferred the Halie to the normal smartinhaler, despite the problems, 
because it's I think individual personalities. I like to keep an eye while he's still 
young, that he's taking it properly’ (Parent of NEMD 10). 
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‘I think it’s good, especially with the teenagers, they like to have gadgets and 
apps, and if they’ve got that ability to have Bluetooth, they can see what they’re 
doing, I think that’s good. Parents, if they want to, can also log in if the kids don’t 
mind, they can see what’s going on. If it does flow and actuation, bonus. That 
would be great’ (CNS 1). 
R-DOT: ‘I don’t like the video idea’ (NEMD 32). 
I don’t know, I think it’s…for people my age, I think they just wouldn’t do it 
because it’s kind of, like, weird.  But maybe for younger people, because then 
it’s like showing how they do it (NEMD 15). 
Rafi-Tone: ‘I think it’s a bit better, because he sees what he’s doing with it, 
rather than just it sitting on the pump, he’s just a bit more interactive with it’ 





If we’ve got a choice of maybe more than one type of adherence, like one might 
work better for someone and the other work for the, so I think if they’ve got more 
choice, then they’re able to make that choice, it’s probably a good thing, 
especially with the teenagers and the adolescents, they do want a bit more 
independence and they don’t want to be…because they’re obviously always 
getting supervised and adherence, and it’s quite key, and obviously if you’re like 
14, 15, 16 years they don’t want their mum or dad kind of looking over them 
making sure they’re going to do it (CNS 2) 
I think probably depending on the patient as well, so initially I think probably 
some of them would be easier, I mean for children who are most…for parents 
who kind of want to distract them more into taking their…and some of them 
probably like the Rafi tone, from a parents’ perspective, and then for those who 
are independent, are getting a bit older, the Hailie is the way forward, and for 
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Supplementary Table 2:  
Baseline demographics of all participants 
 Participants who 
completed study 
Participants who did not 
complete study 
Subjects (%) 18 (51%) 17 (49%) 
Male (Female) 11 (7) 12 (5) 
Age (years)  13.5 (7-16) 10 (6-15) 
ACT/c ACT  score 15.45± 6.23 18.13 ± 5.89 
m-PAQLQ score 4.86 ± 1.8 5.34 ± 1.31 
FEV1 % Pred  77.54 ± 8.83 72.22 ± 18.5 
BDR %  10.58 ± 13.2 15.42 ±16.71 
ICS dose FP equivalent 
mcg/day 
500 (100 - 1000) 400 (100 - 500) 
ACT: Asthma Control Test, c-ACT: Child Asthma Control Test , m-PAQLQ : Mini Paediatric Asthma 
Quality of Life Questionnaire score, ICS: Inhaled corticosteroid, FP: Fluticasone propionate 
equivalence. Figures are quoted as Median (range), mean ±SD 
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Supplementary Table 3:  
Comparison of asthma control, spirometry and quality of life scores 
with each NEMD 
 R-DOT Hailie Rafi-tone INCA 
Participant Numbers 8 6 2 2 
Number of days monitored 54 (8-145) 88.5 (6-120) 25.5 (25-26) 37 (14-60) 
% Adherence 72 ± 13 65 ± 19 87 ±7 No data 
ACT/c-ACT baseline 16 ± 5.6 17 ± 7.9 7 17 ± 4.2 
ACT/c-ACT Follow up  15.2± 8.2 18.7 ±5.1 19 21.5 ± 0.7 
m-PAQLQ Baseline  4.7 ± 2.2 5.1 ± 2.1 4.2 4.31 
m-PAQLQ Follow up 4.9 ± 1.58 5.4 ± 2.1 4.5 6 
FEV1 % predicted Baseline 81 ± 7 77.8± 9 97 60 
FEV1 % predicted Follow up 79 ± 10 85 ± 8 110 85 
FEV1 % predicted p value 0.68 0.17 - - 
FeNO ppb Baseline 37.1 ± 22 53 ± 22 10 86 
FeNO ppb  follow up 40.7 ± 37 46 ± 28 24 12 
Number on biologic therapy 1 2 0 0 
ACT: Asthma Control Test, c-ACT: Child Asthma Control Test , m-PAQLQ : Mini Paediatric Asthma 
Quality of Life Questionnaire score, ICS: Inhaled corticosteroid, FP: Fluticasone propionate 
equivalence. Figures are quoted as Median (range), mean ±SD 
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